{"name":"Gmax Biopharm LLC.","slug":"gmax-biopharm-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFAwY3ZOWWJ0Z3I3VUZ6VjZhZ3ZoaXIyUUZrVDhxWkVOZWhTdEJibG5idk1tV1h2Tzhwa3p5bUxYQ0ZaUmZOcVRRWXlMNGI3YTI4Zkx5QXFEbnk1YkVudXNDQ09ubXJKMks3ZHZv?oc=5","date":"2026-02-06","type":"earnings","source":"Insightace Analytic","summary":"GLP-1 Market Size, Share, Trend, Revenue Report 2026 to 2035 - Insightace Analytic","headline":"GLP-1 Market Size, Share, Trend, Revenue Report 2026 to 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQeHhISHVyb2Z5d2h0aGoyZW4takJhLTlQaDlYbFFlaTRvMnBrN3h6cEttemhWelM0SzRkRFlzVlkzTkdET1dqb2xZcVdjZ0pKWGZIVnd0QnBDRHJjN0J3WXZmaWRpU0g4VndCYk9zSE94dF80VWNWX01MYXpJci02SFozdHlOdlR2TkM0ckNpdjBzVHE5U2hVUzc0U0dMODBXZkNYY08xOFh1OE53eWRRYi03cUIwQlh3d0JvTU41djhNMm9Mc3hBelZldmRETjlQd3ptNmlkY2RuQm9zR1F4WlMzeVQyUnhxeDdBSUNSbjRJX1NLVjI0ZEs0bmY3dWh4dDd1TFZKbjlpNTlIeXdqdm9PWG1mS3hEMTNTTmRjZw?oc=5","date":"2025-01-20","type":"trial","source":"globenewswire.com","summary":"Advancements in Ocular Hypertension Clinical Trial Pipeline - globenewswire.com","headline":"Advancements in Ocular Hypertension Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPTm1iOVZkUkcwdDV3cF90OEpGZ3VLbGdJQ0ZaWDNFa3BlMUF0ZS1CUTB5TWV2eHlFbkh1cXl6RjJFaHZlR1RVLVNTd1FDM19RRExiaEJIYndWWEk5ekp5aUlXNXRNbXFIYkFFUDlhOGdSRlRNZDlSN2IwekIyZ0ZES1FfdTVFY0JacTY3Z3Q3WE9kbUtERl9kVlFIY3Yzd2pqN19Wc1VHeHhNNU9ZZF9wa29qeDNDZC1wVFRFOGVSQTlRdTNNem5XRnJWR1lLNkRJOXBIZ2lSd0E0WU44dXhaaVo1dlkwdjR2Q3F6bUZkM3JkamtCTVYyMEhDQVRZLXBqd0VHWGctQmtLb2tyaC1mSk9RcEZVZ2RtUzdQZDRVcW9oLUV1VHMwbnVvczVlUUFTX3dz?oc=5","date":"2024-07-23","type":"trial","source":"globenewswire.com","summary":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ - globenewswire.com","headline":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-07-19","type":"pipeline","source":"PR Newswire","summary":"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer B","headline":"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Ba","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxNN0JQbDNJNGVXZUdYblFTWU9QV0hWRGlzSTVzRVhwWkF0QXZob21sbWQ0RHN5WURGNVIzVU4zOTdZVGNocDR4ZnNkZGFrNlFkQmRvVGlXdm5rdFA5QzdYSnRlQzlZVTlWRENHRm9CQzVkLWlGQWxtRVprSHRwVkdaSDJQa0xPN2NUcEJSVmRkaVdoeXZJODRqZ25aeGRLU0NMZUtubXJqc2FTRVA3bldBUGFJQU82NDB1NlNZaW1IMTdJb1IxejM5UWctLXJGRThaUGg4SjRqVW9ES0JHX05pUTYybFpZS1NNdGFHa3VYNFl6TFNEQ01CNTNPWHZtaHVa?oc=5","date":"2022-11-14","type":"regulatory","source":"BioSpace","summary":"The World's First ETa-specific Monoclonal Antibody: Gmax Biopharm's GMA131 Approved by the US FDA for Clinical Study on (DKD) Diabetic Kidney Disease - BioSpace","headline":"The World's First ETa-specific Monoclonal Antibody: Gmax Biopharm's GMA131 Approved by the US FDA for Clinical Study on ","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}